

## Heat Biologics Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 18-Feb-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

# Heat Biologics Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Heat Biologics Inc
<b>Parent Company Name</b>	Heat Biologics Inc
<b>Website</b>	http://www.heatbio.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	7
<b>Number of Inactive Drugs</b>	2
<b>Number of Patents as Owner</b>	1
<b>Number of Patents as Third Party</b>	2
<b>Number of Deals</b>	1
<b>Key Indications</b>	Ovary tumor,HIV infection,Non-small-cell lung cancer,Bladder cancer,Breast tumor,Hepatitis C virus infection,Metastatic non small cell lung cancer,Lung tumor,Adenocarcinoma,Cancer,Lymphoma
<b>Key Target-based Actions</b>	Endoplasmin modulator,CD80 modulator,Death receptor-3 antagonist,HLA antigen modulator,Tumor necrosis factor 15 ligand inhibitor,Tumor necrosis factor 15 ligand modulator,Endoplasmin stimulator,B-lymphocyte antigen CD20 inhibitor,CD74 antagonist,CD80 gene stimulator,HIV gp120 protein stimulator,HLA gene stimulator
<b>Key Technologies</b>	Biological therapeutic,Cell therapy,Parenteral formulation unspecified,Protein fusion,Antigen,Antibody fragment,Monoclonal antibody,Injectable formulation,Chimeric antibody,Drug combination,Polynucleotide sequence,Protein recombinant,Tumor antigen,Vector expression

## COMPANY PROFILE

### SUMMARY

Heat Biologics Inc is a clinical-stage company, formed in July 2008, by Seed One Ventures and The University of Miami Miller School of Medicine to advance Heatshock and Inhibitor technology developed by researchers at the University. The company focuses on development of its novel "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy) off-the-shelf therapeutic vaccines to combat a wide range of cancers and other diseases.

### FINANCIAL

In July 2013, Heat Biologics joined the NASDAQ Stock Market under the ticker symbol 'HTBX'.

In July 2013, the company priced an IPO of 2.5 million shares at \$10 per share for gross proceeds of \$25 million. Underwriters were granted a 45-day overallotment option to purchase up to 375,000 additional shares. The offering was expected to close on July 29, 2013. Later that month, the offering was completed. In August 2013, the company announced the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 100,000 shares of its common stock, at a price of \$10 per share. The total gross proceeds from the offering was bought to \$26 million. In September 2013, the company announced the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 100,000 shares of its common stock, at a price of \$10 per share. The total gross proceeds from the offering were expected to be \$27 million.

In May 2010, the company closed an initial round of funding.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	5	0	5
Gynecology and obstetrics	3	0	3
Endocrine disease	3	0	3
Genitourinary disease	3	0	3
Gastrointestinal disease	1	1	2
Respiratory disease	1	1	2
Infectious disease	2	0	2
Inflammatory disease	1	1	2
Surgical procedure	0	1	1
Immune disorder	0	1	1
Prophylaxis	0	1	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)



## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	5
No Development Reported	2

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	1	0	0	0	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	1	3
Genitourinary disease	1	2
Respiratory disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	0	1
Phase 1	1	2

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Hematological disease	0	1	1
Immune disorder	0	1	1

[Return to Table of Contents](#)

Neoplasm	0	2	2
Respiratory disease	0	2	2
Infectious disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### HS-110

<b>Drug Name</b>	HS-110
<b>Key Synonyms</b>	
<b>Originator Company</b>	Heat Biologics Inc
<b>Active Companies</b>	Heat Biologics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Metastatic non small cell lung cancer, Non-small-cell lung cancer
<b>Target-based Actions</b>	HLA antigen modulator, CD80 modulator, Endoplasmic modulator
<b>Other Actions</b>	Genetically engineered autologous cell vaccine, Anticancer, Therapeutic vaccine
<b>Technologies</b>	Cell therapy, Injectable formulation, Antigen, Biological therapeutic, Parenteral formulation unspecified, Protein fusion
<b>Last Change Date</b>	16-Nov-2013

### HS-410

<b>Drug Name</b>	HS-410
<b>Key Synonyms</b>	
<b>Originator Company</b>	Heat Biologics Inc
<b>Active Companies</b>	Heat Biologics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Bladder cancer
<b>Target-based Actions</b>	Endoplasmic modulator
<b>Other Actions</b>	Therapeutic vaccine, Genetically engineered autologous cell vaccine, Anticancer
<b>Technologies</b>	Antibody fragment, Cell therapy, Biological therapeutic, Parenteral formulation unspecified, Protein fusion
<b>Last Change Date</b>	31-Dec-2013

[Return to Table of Contents](#)

## HS-HIV/SIV

<b>Drug Name</b>	HS-HIV/SIV
<b>Key Synonyms</b>	
<b>Originator Company</b>	Heat Biologics Inc
<b>Active Companies</b>	Heat Biologics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	HIV infection
<b>Target-based Actions</b>	Endoplasmin modulator
<b>Other Actions</b>	Prophylactic vaccine, Therapeutic vaccine, Antiviral, Genetically engineered autologous cell vaccine
<b>Technologies</b>	Antibody fragment, Cell therapy, Antigen, Biological therapeutic, Protein fusion
<b>Last Change Date</b>	15-Mar-2013

## HS-HCV

<b>Drug Name</b>	HS-HCV
<b>Key Synonyms</b>	
<b>Originator Company</b>	Heat Biologics Inc
<b>Active Companies</b>	Heat Biologics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hepatitis C virus infection
<b>Target-based Actions</b>	Endoplasmin modulator
<b>Other Actions</b>	Prophylactic vaccine, Genetically engineered autologous cell vaccine, Antiviral, Therapeutic vaccine
<b>Technologies</b>	Cell therapy, Antigen, Biological therapeutic, Parenteral formulation unspecified, Protein fusion
<b>Last Change Date</b>	29-Aug-2013

[Return to Table of Contents](#)



## HS-210

<b>Drug Name</b>	HS-210
<b>Key Synonyms</b>	
<b>Originator Company</b>	Heat Biologics Inc
<b>Active Companies</b>	Heat Biologics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Ovary tumor
<b>Target-based Actions</b>	Endoplasmin modulator
<b>Other Actions</b>	Therapeutic vaccine, Anticancer, Genetically engineered autologous cell vaccine
<b>Technologies</b>	Antibody fragment, Cell therapy, Antigen, Biological therapeutic, Parenteral formulation unspecified, Protein fusion
<b>Last Change Date</b>	19-Jun-2013

## HS-310

<b>Drug Name</b>	HS-310
<b>Key Synonyms</b>	
<b>Originator Company</b>	Heat Biologics Inc
<b>Active Companies</b>	Heat Biologics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Ovary tumor
<b>Target-based Actions</b>	Endoplasmin modulator
<b>Other Actions</b>	Anticancer, Genetically engineered autologous cell vaccine, Therapeutic vaccine
<b>Technologies</b>	Antibody fragment, Cell therapy, Antigen, Biological therapeutic, Parenteral formulation unspecified, Protein fusion
<b>Last Change Date</b>	21-Jun-2013

[Return to Table of Contents](#)

HS-510

Drug Name	HS-510
Key Synonyms	
Originator Company	Heat Biologics Inc
Active Companies	Heat Biologics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Breast tumor
Target-based Actions	
Other Actions	Anticancer
Technologies	Cell therapy, Biological therapeutic
Last Change Date	21-Jun-2013

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)